An International, Multicenter, Open-Label Study of Vorinostat (MK0683) in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

An International, Multicenter, Open-Label Study of Vorinostat (MK0683) in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Vorinostat (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms VANTAGE-095
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 18 Apr 2012 Actual end date changed from Mar 2012 to Apr 2012 as reported by ClinicalTrials.gov.
    • 18 Apr 2012 Actual patients number is 143 as reported by ClinicalTrials.gov.
    • 13 Apr 2012 Actual end date changed from 1 May 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top